Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00135369 | Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen | PHASE3 | COMPLETED | 300 | — | — | Sep 1, 2002 | Jul 1, 2005 | Apr 25, 2011 | 47 | United States, Puerto Rico |
| Name | Type | Description |
|---|---|---|
| stavudine extended-release, lamivudine, efavirenz | DRUG | - |
Inclusion Criteria: * Documented HIV infection * 18 years of age or older and weigh at least 40 kg * Two plasma HIV RNA levels below the limit of quantification (one at least 90 days prior to the screening visit and one within 30 days of the patients baseline visit) * Currently receiving a standard...